Cat. No.: HY-N0890

Tubeimoside I

(Synonyms: Tubeimoside-1; Lobatoside-H)

5 Cited Publications

Avis client

Based on 5 publication(s) in Google Scholar

Tubeimoside I is an orally active HSPD1 inhibitor. Tubeimoside I inhibits NF-κB, MAPK, as well as regulates eNOS-VEGF. Tubeimoside I induces cytoprotective Autophagy via an Akt-mediated pathway. Tubeimoside I inhibits proinflammatory cytokine (IL-6 and IL-1β) production. Tubeimoside I exhibits anti-inflammatory activities. Tubeimoside I promotes angiogenesis and improves sepsis symptoms. Tubeimoside I is used in the research of inflammatory diseases, various cancers, sepsis and ischemic diseases.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.96%
CAS No.: 102040-03-9
Formule: C₆₃H₉₈O₂₉
Masse moléculaire:1319.43

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Tubeimoside I Chemical Structure

CAS No.: 102040-03-9

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (5)
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

Voir tous les produits spécifiques à Isoform HSP :

Voir tous les produits spécifiques à Isoform NF-κB :

Voir tous les produits spécifiques à Isoform p38 MAPK :

Voir tous les produits spécifiques à Isoform Akt :

Voir tous les produits spécifiques à Isoform Interleukin Related :

Voir tous les produits spécifiques à Isoform VEGFR :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	12.3 μM Compound: TBM I	Antiproliferative activity against human A549 cells after 72 hrs by MTS assay Antiproliferative activity against human A549 cells after 72 hrs by MTS assay	[PMID: 30439592]
DU-145	IC₅₀	10 μM Compound: TBM I	Antiproliferative activity against human DU145 cells after 24 hrs by MTT assay Antiproliferative activity against human DU145 cells after 24 hrs by MTT assay	[PMID: 30439592]
HeLa	IC₅₀	17.1 μM Compound: TBM I	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 30439592]
HeLa	IC₅₀	25 μM Compound: TBM I	Cytotoxicity against human HeLa cells after 24 hrs by MTT assay Cytotoxicity against human HeLa cells after 24 hrs by MTT assay	[PMID: 30439592]
HeLa	IC₅₀	27.1 μM Compound: TBM I	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 30439592]
HeLa	IC₅₀	34.8 μM Compound: TBM I	Antiproliferative activity against human HeLa cells after 24 hrs by MTT assay Antiproliferative activity against human HeLa cells after 24 hrs by MTT assay	[PMID: 30439592]
HepG2	IC₅₀	15.5 μM Compound: TBM I	Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 30439592]
HUVEC	IC₅₀	17.9 μM Compound: TBM I	Antiproliferative activity against HUVEC after 72 hrs Antiproliferative activity against HUVEC after 72 hrs	[PMID: 30439592]
HUVEC	IC₅₀	21.4 μM Compound: TBM I	Antiproliferative activity against HUVEC after 48 hrs Antiproliferative activity against HUVEC after 48 hrs	[PMID: 30439592]
HUVEC	IC₅₀	24.2 μM Compound: TBM I	Antiproliferative activity against HUVEC after 24 hrs Antiproliferative activity against HUVEC after 24 hrs	[PMID: 30439592]
JEG-3	IC₅₀	8.5 μM Compound: TBM I	Antiproliferative activity against human JEG3 cells after 24 hrs by MTT assay Antiproliferative activity against human JEG3 cells after 24 hrs by MTT assay	[PMID: 30439592]
NCI-H1299	IC₅₀	10 μM Compound: TBM I	Antiproliferative activity against human NCI-H1299 cells after 48 hrs by CCK-8 assay Antiproliferative activity against human NCI-H1299 cells after 48 hrs by CCK-8 assay	[PMID: 30439592]
NCI-H460	IC₅₀	20 μM Compound: TBM I	Antiproliferative activity against human NCI-H460 cells after 9 hrs by MTT assay Antiproliferative activity against human NCI-H460 cells after 9 hrs by MTT assay	[PMID: 30439592]
NCI-H460	IC₅₀	23.3 μM Compound: TBM I	Antiproliferative activity against human NCI-H460 cells after 24 hrs by WST-1 assay Antiproliferative activity against human NCI-H460 cells after 24 hrs by WST-1 assay	[PMID: 30439592]
PC-3	IC₅₀	20 μM Compound: TBM I	Antiproliferative activity against human PC3 cells after 24 hrs by MTT assay Antiproliferative activity against human PC3 cells after 24 hrs by MTT assay	[PMID: 30439592]
PC-9	IC₅₀	10.2 μM Compound: TBM I	Antiproliferative activity against human PC9 cells after 72 hrs by MTS assay Antiproliferative activity against human PC9 cells after 72 hrs by MTS assay	[PMID: 30439592]
SK-OV-3	IC₅₀	16 μM Compound: TBM I	Antiproliferative activity against human SKOV3 cells after 24 hrs by MTT assay Antiproliferative activity against human SKOV3 cells after 24 hrs by MTT assay	[PMID: 30439592]
T-24	IC₅₀	20 μM Compound: TBM I	Antiproliferative activity against human T24 cells after 24 hrs by MTT assay Antiproliferative activity against human T24 cells after 24 hrs by MTT assay	[PMID: 30439592]

In Vitro

Tubeimoside I (0.5-8 µM; 6-48 h) induces cytoprotective autophagy in human breast cancer cells (MDA-MB-231, MCF-7, T47D) via Akt-mediated pathway^[1].
Tubeimoside I (20 µM; 24 h) inhibits the late stage of autophagic flux in lung cancer cells transfected with mCherry-GFP-LC3 tandem plasmids^[2].
Tubeimoside I (0-30 µM; 24 h) markedly decreases cervical cancer (Hela and SiHa) cell viability in a dose-dependent manner^[3].
Tubeimoside I (25 μM; 4-24 h) causes cell cycle arrest at the G2/M phase in HeLa cells in a dose- and time- dependent manner^[4].
Tubeimoside I (3-15 μM; 12-24 h) induces oxidative stress-mediated apoptosis and G0/G1 phase arrest in human prostate carcinoma cells DU145 and PC3^[5].
Tubeimoside I (15-30 μM; 24 h) induces apoptosis in HepG2 and L-02 cells^[6].
Tubeimoside I (2-6 μM; 1 h) attenuates LPS-induced inflammation in RAW 264.7 cells, inhibiting the production of pro-inflammatory cytokines TNF-α, IL-6 and IL-1β^[7].
Tubeimoside I (0.5-10 μM; 48 h) inhibits the viability of HCT-116 colon cancer cells in a dose-dependent manner^[10].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis^[1]

Cell Line:

MCF-7, MDA-MB-231, T47D
Concentration:

0.5 μM, 1 μM, 2 μM, 4 μM, 8 μM
Incubation Time:

6, 9, 12, 24, 36 h
Result:

Induced apoptosis in a dose-dependent manner, as determined by increased cleaved PARP and caspase-3 levels.
Decreased the levels of Mcl-1, Bcl-xl, and Bcl-2 in a time- and dose- dependent manner.

In Vivo

Tubeimoside I (1-4 mg/kg; i.p.; 13 days) inhibits the growth of tumors in nude mice subcutaneously inoculated with NCI-H1299 cells in a dose-dependent manner and does not cause a decrease in the body weight of the mice^[2].
Tubeimoside I (3 mg/kg; i.p.; daily; 16 days) inhibits the growth of HeLa-xenografted tumors in nude mice, as indicated by smaller tumor size, volume, and mass^[3].
Tubeimoside I (1-4 mg/kg; i.p.; 1 h before LPS challenge) reduces lung injury, down-regulates the secretion of TNF-α, IL-6 and IL-1β, and inhibits the activation of NF-κB and MAPK in a murine model of LPS-induced acute lung injury^[7].
Tubeimoside I (45-180 mg/kg; p.o.; daily; 21 consecutive days) attenuates inflammation and oxidative damage in a mice model of PM_2.5‑induced pulmonary injury^[8].
Tubeimoside I (4 mg/kg; i.p.; 1 h before cecal ligation and puncture (CLP)) improves survival of mice in sepsis by inhibiting inducible nitric oxide synthase expression^[9].
Tubeimoside I (4 mg/kg; i.p.; every day; 28 days) improves recovery from hindlimb ischemia and increases capillary density in C57BL/6 mice^[11].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

5-week-old male BALB/c nude mice (weighing 18-22 g), lung cancer xenograft model established by subcutaneous injection of NCI-H1299 cells^[2]
Dosage:

1 mg/kg, 4 mg/kg
Administration:

Intraperitoneal injection, 13 days
Result:

Reduced the tumor volume and weight.
Significantly upregulated the expression levels of cleaved-PARP, cleaved-caspase 3, LC3-II, and p62 in the tumor tissues.

Animal Model:

Female BALB/c nude mice (4-week-old) with HeLa cell xenograft model^[3]
Dosage:

3 mg/kg
Administration:

Intraperitoneal injection, daily, for 16 days
Result:

Decreased the expression of Ki67 in tumor tissues, indicating reduced proliferating ability.
Induced tumor cell apoptosis, as evidenced by the accumulation of cleaved-CASP3 and cleaved-PARP1 in tumor tissues.
Induced autophagosome accumulation in tumor cells, with increased LC3 II expression and enhanced LC3 staining in tumor tissues.

Chemical Information

CAS No. 102040-03-9
Appearance Solid
Masse moléculaire 1319.43
Formule C₆₃H₉₈O₂₉
Color White to off-white
SMILES

C[C@@]12C([C@@]3([H])[C@](C(O[C@@H]4OC[C@H](O)[C@H](O)[C@H]4O[C@@H]5O[C@@H](C)[C@H](OC(C[C@](O)(C)CC6=O)=O)[C@@H](O[C@@H]7OC[C@@H](O)[C@H](O)[C@H]7O)[C@H]5O)=O)(CCC(C)(C)C3)CC2)=CC[C@@]8([H])[C@@]1(C)CC[C@]([C@](C)(CO)[C@H]9O[C@@H]%10O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%10O[C@@H]%11OC[C@H](O6)[C@H](O)[C@H]%11O)([H])[C@]8(C)C[C@@H]9O
Synonyms

Tubeimoside-1; Lobatoside-H
Structure Classification
- Terpenoids
- Triterpenes
Initial Source
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (5)

All Cell Proliferation/Viability AssayFlow CytometryWBIFIn Vivo Efficacy Study

Sort by:

Journal Impact Factor

Pharmacol Res

Cardamonin retards progression of autosomal dominant polycystic kidney disease via inhibiting renal cyst growth and interstitial fibrosis. [Abstract]

2020 May:155:104751. PMID: 32151678
Phytomedicine

Tubeimoside Ⅰ targets sodium/potassium ATPase alpha 1 subunit to selectively eliminate senescent cells and alleviate aging-associated abnormalities. [Abstract]

2026 Jul:156:158202. PMID: 42035526
Transl Oncol

Tubeimoside I induces mitophagy by activating the PINK1/Parkin/Mfn2 signaling pathway in acute myeloid leukemia cells. [Abstract]

2025 May:55:102355. PMID: 40112502

Tubeimoside I purchased from MedChemExpress. Usage Cited in: Transl Oncol. 2025 May:55:102355. [Abstract]

Cell viability was assessed after PBS and TBMS1 (Tubeimoside I) treatment for 24 and 48 hours.

Tubeimoside I purchased from MedChemExpress. Usage Cited in: Transl Oncol. 2025 May:55:102355. [Abstract]

Annexin V-PI flow cytometry analysis of apoptosis in AML cells treated with TBMS1 (Tubeimoside I) for 24 hours.

Tubeimoside I purchased from MedChemExpress. Usage Cited in: Transl Oncol. 2025 May:55:102355. [Abstract]

TBMS1 (Tubeimoside I) induces mitophagy in AML cells. The expression of autophagy-related proteins was detected by Western blot.

Tubeimoside I purchased from MedChemExpress. Usage Cited in: Transl Oncol. 2025 May:55:102355. [Abstract]

TBMS1 (Tubeimoside I) induces mitophagy in AML cells. LC3B protein expression was detected by confocal microscopy.

Tubeimoside I purchased from MedChemExpress. Usage Cited in: Transl Oncol. 2025 May:55:102355. [Abstract]

Tumor weight and volume after 21 days of treatment with saline and TBMS1 (Tubeimoside I: 5 mg/kg).
Biochem Biophys Res Commun

Engineered MAP30ER: A plant toxin-derived platform for EGFR-Targeted delivery of protein and chemotherapeutic payloads. [Abstract]

2025 Aug 30:776:152184. PMID: 40517671
Oxid Med Cell Longev

Tubeimoside I Ameliorates Doxorubicin-Induced Cardiotoxicity by Upregulating SIRT3. [Abstract]

2023 Jan 14:2023:9966355. PMID: 36691640

Solvant et solubilité

In Vitro:

DMSO : 50 mg/mL (37.90 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

0.7579 mL

3.7895 mL

7.5790 mL

5 mM

0.1516 mL

0.7579 mL

1.5158 mL

10 mM

0.0758 mL

0.3790 mL

0.7579 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (1.89 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (1.89 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (1.89 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (298 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Jiang SL, et al. Tubeimoside-1, a triterpenoid saponin, induces cytoprotective autophagy in human breast cancer cells in vitro via Akt-mediated pathway. Acta Pharmacol Sin. 2019 Jul;40(7):919-928. [Content Brief]

[2]. Wang K, et al. Tubeimoside I-induced lung cancer cell death and the underlying crosstalk between lysosomes and mitochondria. Cell Death Dis. 2020 Aug 26;11(8):708. [Content Brief]

[3]. Feng X, et al. Tubeimoside I induces accumulation of impaired autophagolysosome against cervical cancer cells by both initiating autophagy and inhibiting lysosomal function. Cell Death Dis. 2018 Nov 2;9(11):1117. [Content Brief]

[4]. Xu Y, et al. Multiple pathways were involved in tubeimoside-1-induced cytotoxicity of HeLa cells. J Proteomics. 2011 Dec 21;75(2):491-501. [Content Brief]

[5]. Yang JB, et al. Tubeimoside-1 induces oxidative stress-mediated apoptosis and G0/G1 phase arrest in human prostate carcinoma cells in vitro. Acta Pharmacol Sin. 2016 Jul;37(7):950-62. [Content Brief]

[6]. Wang Y, et al. Natural plant extract tubeimoside I promotes apoptosis-mediated cell death in cultured human hepatoma (HepG2) cells. Biol Pharm Bull. 2011;34(6):831-8. [Content Brief]

[7]. Wu Q, et al. Tubeimoside-1 attenuates LPS-induced inflammation in RAW 264.7 macrophages and mouse models. Immunopharmacol Immunotoxicol. 2013 Aug;35(4):514-23. [Content Brief]

[8]. Zhang JB, et al. Tubeimoside I attenuates inflammation and oxidative damage in a mice model of PM2.5-induced pulmonary injury. Exp Ther Med. 2018 Feb;15(2):1602-1607. [Content Brief]

[9]. Luo M, et al.Tubeimoside I improves survival of mice in sepsis by inhibiting inducible nitric oxide synthase expression. Biomed Pharmacother. 2020 Jun;126:110083. [Content Brief]

[10]. Wu T, et al. Tubeimoside-I, an inhibitor of HSPD1, enhances cytotoxicity of oxaliplatin by activating ER stress and MAPK signaling pathways in colorectal cancer. J Ethnopharmacol. 2025 Jan 10;336:118754. [Content Brief]

[11]. Yang X, et al. Tubeimoside I promotes angiogenesis via activation of eNOS-VEGF signaling pathway. J Ethnopharmacol. 2021 Mar 1;267:113642. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	0.7579 mL	3.7895 mL	7.5790 mL	18.9476 mL
	5 mM	0.1516 mL	0.7579 mL	1.5158 mL	3.7895 mL
	10 mM	0.0758 mL	0.3790 mL	0.7579 mL	1.8948 mL
	15 mM	0.0505 mL	0.2526 mL	0.5053 mL	1.2632 mL
	20 mM	0.0379 mL	0.1895 mL	0.3790 mL	0.9474 mL
	25 mM	0.0303 mL	0.1516 mL	0.3032 mL	0.7579 mL
	30 mM	0.0253 mL	0.1263 mL	0.2526 mL	0.6316 mL

Keywords

Tubeimoside I

5 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Tubeimoside I

Cell Cycle/DNA Damage Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

MAPK Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

PI3K/Akt/mTOR Compound Library

Protein Tyrosine Kinase Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Macrocyclic Compound Library

Glycoside Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

Medicine Food Homology Compound Library

Terpenoids Library

Glycolysis Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Glucose Metabolism Compound Library

Anti-Liver Cancer Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Autoimmune Disease Compound Library

Cytokine Inhibitors Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Miao Ethnicity Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Anti-Rheumatic Arthritis Compound Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Tubeimoside I